Phase IB dose-escalation and expansion study of AKT kinase inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer by Blagden, S, Hamilton, A, Mileshkin, L, Wong, S, Michael, A, Hall, M, Goh, J, Lisyanskaya, A, Desilvio, M, Frangou, E, Stronach, E, Gopalakrishna, P, Meniawy, T, Gabra, H

Dose-finding quantitative 18F-FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecological malignancies by Gungor, H, Saleem, A, Babar, S, Dina, R, El-Bahrawy, M, Curry, E, Rama, N, Chen, M, Pickford, E, Agarwal, R, Blagden, S, Carme, S, Salinas, C, Madison, S, Krachey, E, Santiago-Walker, A, Smith, D, Morris, S, Stronach, E, Gabra, H